In addition, the cIMPACT-NOW update 3 recommends that IDH wild-type LGG harboring EGFR gene amplifications, chromosome 7 gain and chromosome 10 loss, or TERT promoter mutations will follow an invasive clinical course similar to IDH wild-type glioblastoma and patients with this condition have significantly shorter survival (5). This evidence concerns the gene IDH2 and glioblastoma.